Overview Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression Status: ACTIVE_NOT_RECRUITING Trial end date: 2025-12-01 Target enrollment: Participant gender: Summary The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)Phase: PHASE2 Details Lead Sponsor: Biohaven Therapeutics Ltd.